Fig. 4. NRBP1 is required for efficient TNBC xenograft growth and experimental metastasis.

A NRBP1 knockdown reduces growth of MDA-MB-231_HM orthotopic xenografts. Representative whole body BLI images from each group at different time points are shown. NTC, non-targeting control. B Quantification of xenograft growth. Mean tumour luciferase intensities over time were measured as mean photon counts per sec. Each group exhibited n ≥ 8 mice. C Quantification of tumour weight. Data at Day 34 post-injection were obtained from NTC (n = 6), shNRBP1#1 (n = 8) and shNRBP1#2 (n = 9) mice. Three mice from the original NTC group reached ethical endpoint earlier at Day 27 and were excluded from the tumour weight analysis. However, these mice were used for IHC analysis (below). D Confirmation of NRBP1 knockdown by IHC. E NRBP1 knockdown reduces tumour cell proliferation. Representative IHC staining for Ki67 is shown. For D, E, data were quantified from NTC (n = 9), shNRBP1#1 (n = 8) and shNRBP1#2 (n = 9) mice. All xenografts were collected at the endpoint of experiment (at Day 34), except for three xenografts from control mice that were collected at Day 27 when tumour reached ethical endpoint. F NRBP1 is required for efficient TNBC metastasis. Left panel, representative whole body BLI images from each group at Day 56. Right panel, luciferase intensities of tumour metastasis to lung were generated from NTC (n = 6), shNRBP1#1 (n = 6) and shNRBP1#2 (n = 8) mice. For B–F, error bars represent the standard error of the mean. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 by two-way ANOVA with Dunnett’s multiple comparison test (B), or one-way ANOVA with Dunnett’s multiple comparisons test (C–F).